Table 1.
Demographic characteristics for AYA with SCD across Phases 1, 2, and 3 (N = 70)
| Phase 1 (n = 46) | Phase 2 (n = 19) | Phase 3 (n = 5) | |
|---|---|---|---|
| Ma (SD)b | |||
| Age | 19.5 (2.4) | 20.39 (2.4) | 14.2 (1.9) |
| Annual Hospitalizations | 1.2 (2.1) | 4.24 (2.9)d | 0.8 (0.4) |
| N (%) | |||
| Gender | |||
| Female | 27 (41) | 12 (63.2) | 3 (60) |
| Male | 19 (59) | 7 (36.8) | 2 (40) |
| Race/Ethnicity | |||
| African American | 45 (100)c | 19 (100) | 5 (100) |
| SCD Genotype | |||
| HbSS | 34 (74) | 13 (68.4) | 3 (60) |
| HbSC | 6 (13) | 5 (26.3) | 2 (40) |
| HbS Beta Thal | 5 (11) | 1 (5.3) | --- |
| HbSD | 1 (2) | --- | --- |
| Insurance | |||
| Public | 35 (76) | 12 (63.2) | 4 (80) |
| Private | 11 (24) | 2 (10.5) | 1 (20) |
| Both | --- | 1 (5.3) | --- |
| None | --- | 4 (21.1) | --- |
a)
Mean,
b)
Standard deviation,
c)
Includes missing data (n = 45),
d)
Includes missing data (n = 17).
Note. Sample demographics were consistent with data from the overall clinic sample (N=88) at the time of the baseline study, including mean age (M=20.18, SD=2.48), gender (53% female; 47% male) and SCD type (66% HbSS; 18% HbSC; 14% HbSβthal; 1% HbSD; 1% S Hope).